otelixizumab

Home
Ligands
otelixizumab

GtoPdb Ligand ID: 8458

Synonyms: ChAglyCD3 | TRX4

Comment: Otelixizumab is a chimeric humanized IgG1 monoclonal antibody targeting the CD3E component of the T cell receptor. The antibody is aglycosylated. Otelixizumab was investigated as a potential treatment for autoimmune diseases including type I diabetes [3-4].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol, 23 (2): 403-11. [PMID:8436176]
2. Chatenoud L, Bluestone JA. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol, 7 (8): 622-32. [PMID:17641665]
3. Kaufman A, Herold KC. (2009) Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev, 25 (4): 302-6. [PMID:19319985]
4. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al.. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med, 352 (25): 2598-608. [PMID:15972866]
5. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, Bode B, Aronoff S, Holland C, Carlin D et al.. (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet, 378 (9790): 487-97. [PMID:21719095]

References

1. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993)
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Eur J Immunol, 23 (2): 403-11. [PMID:8436176]

2. Chatenoud L, Bluestone JA. (2007)
CD3-specific antibodies: a portal to the treatment of autoimmunity.
Nat Rev Immunol, 7 (8): 622-32. [PMID:17641665]

3. Kaufman A, Herold KC. (2009)
Anti-CD3 mAbs for treatment of type 1 diabetes.
Diabetes Metab Res Rev, 25 (4): 302-6. [PMID:19319985]

4. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al.. (2005)
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
N Engl J Med, 352 (25): 2598-608. [PMID:15972866]

5. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, Bode B, Aronoff S, Holland C, Carlin D et al.. (2011)
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Lancet, 378 (9790): 487-97. [PMID:21719095]